Lyrica is the original innovator oral solid pharmaceutical brand containing pregabalin<\/b> (developed and commercialized by Pfizer). Chemically designated as $(3S)\\text{-3-(aminomethyl)-5-methylhexanoic acid}$<\/span>, pregabalin is a synthetic branched-chain aliphatic carboxylic acid belonging to the gabapentinoid<\/b> chemical class. Structurally, it is an alkylated structural analogue of the principal inhibitory neurotransmitter $\\gamma\\text{-aminobutyric acid}$<\/span> (GABA), featuring an isobutyl substitution at the carbon-3 ($\\beta$<\/span>) position. It is synthesized and formulated exclusively as the biologically active $(S)\\text{-enantiomer}$<\/span>. Its empirical formula is $\\text{C}_8\\text{H}_{17}\\text{NO}_2$<\/span>, with a molecular weight of $159.23\\text{ g\/mol}$<\/span>.<\/p>\n In the United Kingdom, Lyrica is presented as hard gelatin capsules across a comprehensive spectrum of standardized strength tiers, each differentiated by capsule shell color and debossed branding (imprinted with black ink indicating “Pfizer” on the cap and the code “PGN [strength]” on the body):<\/p>\n 25mg:<\/b> White body \/ white cap (debossed “PGN 25”)<\/p>\n<\/li>\n 50mg:<\/b> White body \/ white cap with black band (debossed “PGN 50”)<\/p>\n<\/li>\n 75mg:<\/b> White body \/ orange cap (debossed “PGN 75”)<\/p>\n<\/li>\n 100mg:<\/b> Orange body \/ orange cap (debossed “PGN 100”)<\/p>\n<\/li>\n 150mg:<\/b> White body \/ white cap (debossed “PGN 150”)<\/p>\n<\/li>\n 200mg:<\/b> Light orange body \/ light orange cap (debossed “PGN 200”)<\/p>\n<\/li>\n 225mg:<\/b> White body \/ light orange cap (debossed “PGN 225”)<\/p>\n<\/li>\n 300mg:<\/b> White body \/ orange cap (debossed “PGN 300”)<\/p>\n<\/li>\n<\/ul>\n Standard non-active pharmaceutical excipients within the capsule core include lactose monohydrate, pregelatinized maize starch, and talc. The capsule shells are composed of gelatin, titanium dioxide (E171), and iron oxide red\/yellow (E172) for colored variants.<\/p>\n Within the United Kingdom regulatory framework:<\/p>\n Medicinal Classification:<\/b> Categorized as a Prescription Only Medicine (POM)<\/b> governed by the Human Medicines Regulations 2012.<\/p>\n<\/li>\n Controlled Drug Rescheduling (2019):<\/b> Following extensive clinical toxicology alerts, rising coroner death notifications, and formal advisory reports from the Advisory Council on the Misuse of Drugs (ACMD) regarding rising diversion and recreational misuse, pregabalin was officially reclassified in April 2019 as a Class C controlled substance under the Misuse of Drugs Act 1971 and placed into Schedule 3 (CD No Register POM) under the Misuse of Drugs Regulations 2001<\/b>.<\/p>\n<\/li>\n Statutory Prescription Requirements:<\/b> As a Schedule 3 Controlled Drug:<\/p>\n Prescriptions are legally valid for a maximum of 28 days<\/b> from the date of signing.<\/p>\n<\/li>\n Prescriptions must comply with strict statutory Controlled Drug requirements (the exact formulation, strength, dosing instructions, and total quantity written in both words and figures<\/b>).<\/p>\n<\/li>\n Repeat dispensing (batch prescribing) is prohibited.<\/p>\n<\/li>\n It is legally exempt from statutory Safe Custody register-logging requirements in registered retail community pharmacies.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n NHS Formulary Positioning:<\/b> Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff for licensed neuropathic, epileptic, and anxiety indications.<\/p>\n<\/li>\n<\/ul>\n In community addiction landscapes and post-mortem toxicology, diverted pharmaceutical Lyrica or counterfeit pressed capsules (often dubbed “Buds”, “Pregabs”, or “Signature”) represent a substantial public health threat. Illicit capsules acquired via street markets or online platforms routinely exhibit severe dosage inconsistencies or carry active adulteration with illicit designer benzodiazepines (e.g., bromazolam) or synthetic nitazene opioids<\/b>, significantly multiplying overdose lethality.<\/p>\n Despite being a structural analogue of GABA, pregabalin displays no direct binding affinity for $GABA_A$<\/span>, $GABA_B$<\/span>, or benzodiazepine receptor sites<\/b>. It does not metabolize into GABA, does not alter physiological GABA reuptake, and does not inhibit GABA transaminase:<\/p>\n High-Affinity Binding to Voltage-Gated Calcium Channel $\\alpha_2\\delta$<\/span> Subunits:<\/b><\/p>\n Pregabalin exerts its clinical effects by binding with high stereospecific affinity to the auxiliary $\\alpha_2\\delta\\text{-1}$<\/span> and $\\alpha_2\\delta\\text{-2}$<\/span> protein subunits<\/b> of presynaptic voltage-gated calcium channels (VGCCs) concentrated throughout the neocortex, amygdala, hippocampus, and the superficial dorsal horn of the spinal cord.<\/p>\n<\/li>\n Its binding affinity ($K_d \\approx 30\\text{ to }40\\text{ nM}$<\/span>) is roughly six times greater than that of gabapentin<\/b>, conferring its significantly higher clinical potency per milligram.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Presynaptic Calcium Influx Blunting and Neurotransmitter Suppression:<\/b><\/p>\n In hyperexcitable or pathologically sensitized states (such as damaged sensory neurons in peripheral neuropathy or overactive fear networks in generalized anxiety), presynaptic VGCC density is markedly upregulated.<\/p>\n<\/li>\n Occupancy of the $\\alpha_2\\delta$<\/span> subunit by pregabalin blunts depolarization-induced calcium ($Ca^{2+}$<\/span>) influx through the presynaptic terminal.<\/p>\n<\/li>\n Reduced intracellular calcium entry prevents the vesicular docking and exocytosis of primary excitatory neurotransmitters, notably L-glutamate, substance P, calcitonin gene-related peptide (CGRP), and noradrenaline<\/b>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Normalization of Neuronal Hyperexcitability:<\/b><\/p>\n By dampening excessive excitatory transmission without completely abolishing basal synaptic firing, pregabalin produces targeted analgesia, anticonvulsant activity, and anxiolysis.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Secondary Neurochemical Adaptations:<\/b><\/p>\n Sustained exposure impairs the forward trafficking and cell-surface membrane insertion of functional $\\alpha_2\\delta$<\/span> subunits from intracellular stores.<\/p>\n<\/li>\n It produces downstream modulations of non-vesicular GABA transport density over prolonged maintenance.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Receptor Non-Interactions:<\/b> Pregabalin displays no direct affinity for human $\\mu$<\/span>-, $\\kappa$<\/span>-, or $\\delta$<\/span>-opioid receptors, serotonin receptors, dopamine receptors, or peripheral autonomic adrenoceptors.<\/p>\n<\/li>\n<\/ul>\n Lyrica holds licensed therapeutic indications within the British National Formulary (BNF) and National Institute for Health and Care Excellence (NICE) guidelines:<\/p>\n Peripheral and Central Neuropathic Pain:<\/b><\/p>\n Indicated for the treatment of peripheral neuropathic pain (e.g., painful diabetic peripheral neuropathy, post-herpetic neuralgia) and central neuropathic pain (e.g., spinal cord injury, central post-stroke pain).<\/p>\n<\/li>\n Evaluated within NICE Guideline CG173 (Neuropathic pain in adults)<\/b>, where pregabalin is positioned as a first-line pharmacological option alongside amitriptyline, duloxetine, and gabapentin.<\/p>\n<\/li>\n Standard Dosing:<\/i> Initiated at $150\\text{ mg\/day}$<\/span><\/b> in two or three divided doses (e.g., $75\\text{ mg}$<\/span> BD or $50\\text{ mg}$<\/span> TDS). Based on efficacy and tolerability, the dose may be increased to $300\\text{ mg\/day}$<\/span> after 3 to 7 days, and titrated to a maximum ceiling of $600\\text{ mg\/day}$<\/span><\/b> after an additional 7-day interval.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Epilepsy (Adjunctive Therapy for Focal Seizures):<\/b><\/p>\n Indicated as adjunctive therapy in adults with focal seizures, with or without secondary generalization.<\/p>\n<\/li>\n Positioned in NICE Guideline NG217 (Epilepsies)<\/b>. Dosing matches neuropathic schedules, titrating from $150\\text{ mg\/day}$<\/span> up to $600\\text{ mg\/day}$<\/span> in divided doses.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Generalized Anxiety Disorder (GAD):<\/b><\/p>\n Indicated for the treatment of Generalized Anxiety Disorder in adults.<\/p>\n<\/li>\n Evaluated within NICE Guideline CG113 (Anxiety disorders)<\/b>, where pregabalin is recommended for individuals refractory to, or intolerant of, first-line selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs). Initial dose: $150\\text{ mg\/day}$<\/span> divided into two or three doses, titrating incrementally up to $300\\text{ to }600\\text{ mg\/day}$<\/span>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Fibromyalgia (Off-Label UK Specialist Use):<\/b><\/p>\n Frequently prescribed off-label by rheumatologists and chronic pain specialists for central sensitization, widespread body aching, and associated sleep fragmentation ($150\\text{ to }450\\text{ mg\/day}$<\/span>).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n In non-medical, illicit environments, Lyrica is misused for:<\/p>\n Recreational Intoxication:<\/b> Large oral doses ($300\\text{ to }1,200+\\text{ mg}$<\/span>) produce an empathogenic, disinhibited, euphoric, and dissociative state (often described as a hybrid between alcohol intoxication and MDMA-like sensations).<\/p>\n<\/li>\n Opioid Withdrawal Self-Management:<\/b> Ingested in supratherapeutic amounts by individuals with opioid use disorder to suppress the severe autonomic surges, restless legs, and muscle spasms of acute opioid withdrawal.<\/p>\n<\/li>\n Polydrug Potentiation:<\/b> Co-administered with illicit opioids (heroin, methadone) or benzodiazepines to potentiate central sedative and euphoric effects.<\/p>\n<\/li>\n<\/ul>\n The pharmacokinetic profile of Lyrica is characterized by rapid, complete intestinal absorption via active carrier-mediated transport, lack of hepatic metabolism, and exclusive renal elimination:<\/p>\n LAT1 Active Transport:<\/b> Pregabalin is absorbed across the upper gastrointestinal mucosa via the system L-neutral amino acid transporter (LAT1 \/ SLC7A5)<\/b>.<\/p>\n<\/li>\n Predictable Linear Kinetics:<\/b> Unlike gabapentin\u2014which saturates LAT1 at therapeutic doses, causing bioavailability to fall sharply as dose increases\u2014pregabalin displays linear, dose-proportional pharmacokinetics<\/b> across its entire therapeutic range ($75\\text{ to }600\\text{ mg\/day}$<\/span>).<\/p>\n<\/li>\n Food Effects:<\/b> Co-ingestion with food slows the absorption rate, decreasing $C_{max}$<\/span> by approximately $25\\text{ to }30\\%$<\/span> and delaying $T_{max}$<\/span> to approximately 2.5 hours, but does not alter the total area under the curve ($AUC$<\/span>). Capsules can be taken with or without food.<\/p>\n<\/li>\n<\/ul>\n Pregabalin undergoes negligible biotransformation in humans. Less than $2\\%$<\/span> is metabolized, with only trace amounts of an inactive $N\\text{-methylated}$<\/span> derivative detected in urine.<\/p>\n<\/li>\n It does not induce or inhibit CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4, avoiding cytochrome-mediated drug interactions.<\/p>\n<\/li>\n Systemic clearance is directly proportional to creatinine clearance ($\\text{CrCl}$<\/span>). In patients with renal impairment, the elimination half-life is substantially prolonged (exceeding $14\\text{ to }20+\\text{ hours}$<\/span> in moderate-to-severe CKD<\/b>), requiring mandatory dose reductions.<\/p>\n<\/li>\n Pregabalin is readily dialyzable: a standard 4-hour hemodialysis session clears approximately $50\\%$<\/span> of circulating drug from the blood.<\/p>\n<\/li>\n<\/ul>\n Therapeutic administration stabilizes hyperexcitable neural pathways, mitigating neuropathic allodynia, suppressing focal seizure propagation, and blunting autonomic anxiety. However, widespread central $\\alpha_2\\delta$<\/span> modulation produces a broad adverse event spectrum:<\/p>\n Central Nervous System and Cognitive Effects (Very Common, $\\ge 1\/10$<\/span>):<\/b><\/p>\n Dizziness and Somnolence:<\/b> The most common adverse effects, reported in over $25\\text{ to }35\\%$<\/span> of patients. Frequently dose-dependent, typically appearing during titration and often attenuating over several weeks of continuous therapy.<\/p>\n<\/li>\n Cognitive Clouding: Attention deficits, psychomotor slowing, memory impairment, confusion, and dysarthria (slurred speech).<\/p>\n<\/li>\n Cerebellar Ataxia and Incoordination: Motor unsteadiness, gait abnormalities, and tremors, significantly increasing the incidence of falls and fractures in elderly populations.<\/p>\n<\/li>\n Euphoria: Reported in $1\\text{ to }10\\%$<\/span> of clinical trial participants, contributing to its intrinsic abuse liability.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Ophthalmic Disturbances (Common, $1\/100$<\/span> to $<1\/10$<\/span>):<\/b><\/p>\n Blurred vision, diplopia (double vision), and visual field changes resulting from central visual pathway modulation.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Metabolic and Hemodynamic Effects (Common):<\/b><\/p>\n Peripheral Oedema:<\/b> Dose-dependent fluid retention presenting as bilateral lower-extremity pitting oedema (incidence $5\\text{ to }15\\%$<\/span>). Driven by microvascular tone alterations.<\/p>\n<\/li>\n Weight Gain:<\/b> Driven by increased appetite (hyperphagia) combined with fluid retention; long-term therapy produces clinically significant weight gain ($>7\\%$<\/span> increase from baseline) in up to $15\\%$<\/span> of patients.<\/p>\n<\/li>\n Exacerbation of Heart Failure: Fluid retention can precipitate acute decompensation in patients with baseline NYHA Class III\u2013IV congestive heart failure.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe, Emergent and Life-Threatening Hazards:<\/b><\/p>\n\n
\n
\n
2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
\n
\n
\n
\n
3. Approved UK Clinical Indications and Therapeutic Scope<\/h2>\n
\n
\n
\n
\n
\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n\n
\n Pharmacokinetic Parameter<\/strong><\/td>\n Value \/ Metric<\/strong><\/td>\n Clinical Interpretation<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Oral Bioavailability<\/b><\/span><\/td>\n $\\ge 90\\%$<\/span><\/b><\/span><\/td>\n High, consistent, and independent of dose.<\/span><\/td>\n<\/tr>\n \n Peak Concentration ($T_{max}$<\/span>)<\/b><\/span><\/td>\n $0.7\\text{ to }1.3\\text{ hours}$<\/span><\/b> (fasted state)<\/span><\/td>\n Rapid gastrointestinal absorption and rapid onset.<\/span><\/td>\n<\/tr>\n \n Volume of Distribution ($V_d$<\/span>)<\/b><\/span><\/td>\n $\\sim 0.56\\text{ L\/kg}$<\/span><\/b><\/span><\/td>\n Distributes into total body water; crosses blood-brain barrier.<\/span><\/td>\n<\/tr>\n \n Plasma Protein Binding<\/b><\/span><\/td>\n $0\\%$<\/span> (None)<\/b><\/span><\/td>\n Completely unbound in circulating plasma; zero displacement interactions.<\/span><\/td>\n<\/tr>\n \n Hepatic Metabolism<\/b><\/span><\/td>\n $<2\\%$<\/span> (Negligible)<\/b><\/span><\/td>\n Does not interact with cytochrome P450 isoenzymes.<\/span><\/td>\n<\/tr>\n \n Primary Elimination Pathway<\/b><\/span><\/td>\n Renal ($98\\%$<\/span> unchanged)<\/b><\/span><\/td>\n Excreted via glomerular filtration; directly tied to renal function.<\/span><\/td>\n<\/tr>\n \n Elimination Half-Life ($t_{1\/2}$<\/span>)<\/b><\/span><\/td>\n $5.5\\text{ to }6.7\\text{ hours}$<\/span><\/b><\/span><\/td>\n Short half-life requires 2 to 3 divided daily doses.<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Absorption Kinetics (Linearity vs. Gabapentin)<\/h3>\n
\n
Biotransformation and Renal Clearance<\/h3>\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
\n
\n
\n
\n
\n